Abstract
Tolterodine is a potent muscarinic antagonist for M1–M5 subtype receptors. Although nonselective, it has been shown to target the bladder preferentially over other organ systems. It is available in two forms; either as a 1 or 2 mg immediate-release formulation taken twice daily or a 2- or 4-mg extended-release formulation taken daily. In multiple trials, compared with other anticholinergic agents, it has been demonstrated to be effective in the treatment of adult females with an overactive bladder with and without urge incontinence, as well as in those with urge-predominant mixed incontinence. It is well tolerated and safe, with the extended-release formula demonstrating a lower frequency of adverse events, especially dry mouth.